Argenx Has Delivered 18 Consecutive Quarters of Sales Growth -- but Is the Biotech Stock Still Underrated?
Key PointsArgenx's top and bottom lines are growing robustly.
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.